Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-29

Study Completion Date

2021-06-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet

NCT04388215

Hypertension Dyslipidemias

UNKNOWN PHASE3

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia

NCT05657574

Primary Hypercholesterolemia

UNKNOWN PHASE3

A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337

NCT03346187

Dyslipidemias

COMPLETED PHASE1

Clinical Trial to Evaluate the Efficacy and Safety of DP-R212

NCT02955368

Hypertension Hypercholesterolemia

WITHDRAWN PHASE3

Clinical Trial to Evaluate the Efficacy and Safety of CKD-391

NCT02451098

Hyperlipidemia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyslipidemia Patients With Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental Group 1

Group Type EXPERIMENTAL

D013, D326, D337

Intervention Type DRUG

Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337

Comparator Group 1

Group Type PLACEBO_COMPARATOR

placebo of D013, D326, D337

Intervention Type DRUG

Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013

Comparator Group 2

Group Type PLACEBO_COMPARATOR

D013, placebo of D326, placebo of D337

Intervention Type DRUG

Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

D013, D326, D337

Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337

Intervention Type DRUG

placebo of D013, D326, D337

Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013

Intervention Type DRUG

D013, placebo of D326, placebo of D337

Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Drugs are consist of antihypertensive agent and antihyperlipidemic agent Drugs are consist of antihypertensive agent and antihyperlipidemic agent Drugs are consist of antihypertensive agent and antihyperlipidemic agent

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects are diagnosed with Dyslipidemia Patients with Hypertension or are being administered anti-hypertension and anti-hypertension drugs after diagnosis.
2. Subjects who agreed to participate in this clinical trial voluntarily.

Exclusion Criteria

1. Subjects who were satisfied specific blood pressure levels that measured at screening period.
2. Subjects who were satisfied specific lipid levels that measured at screening period.
3. Subjects who cannot participate in a clinical trial based on the PI's judgment.

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No